Pharmacogenomics of Multiple Sclerosis: Sieving treatment biomarkers from blood gene-expression profiles (PP-30)
Introduction: Over the past two decades, various novel disease-modifying drugs for multiple sclerosis (MS) have been approved. However, there is high variability in the patient response to the available medications, which is hypothesized to be partly attributed to genetics. our aim was To conduct a...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Iran University of Medical Sciences
2023-01-01
|
Series: | Neurology Letters |
Subjects: | |
Online Access: | https://www.neurologyletters.com/article_186580_d41d8cd98f00b204e9800998ecf8427e.pdf |